宁波韵升寻求香港上市；信达生物获得DMX-200授权

本文如何被排名

Signal score

0 / 100

Composite score across the factors below. Higher = stronger signal that this story matters right now.

Newsworthiness bucket

Research

该集群包含一家公司提交IPO申请以及一项重要的候选药物授权交易。[lever_c_demoted from significant: ic=1 ai=0.1]

Source corroboration

Single-source cluster

Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.

Topics

funding, product

Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.

AI-industry relevance

Low

Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.

Story freshness

106 days old

Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

完整方法见我们的编辑标准。